Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non-small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually. Materials and methods: This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed. Results: Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832). Conclusion: The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies.
Abstract
Purpose: Since tumor mutational burden (TMB) and gene expression profiling (GEP) have complementary effects, they may have improved predictive power when used in combination. Here, we investigated the ability of TMB and GEP to predict the immunotherapy response in patients with non-small cell lung cancer (NSCLC) and assessed if this combination can improve predictive power compared to that when used individually. Materials and methods: This retrospective cohort study included 30 patients with NSCLC who received immune checkpoint inhibitors (ICI) therapy at the Seoul National University Bundang Hospital. programmed cell death-ligand-1 (PD-L1) protein expression was assessed using immunohistochemistry, and TMB was measured by targeted deep sequencing. Gene expression was determined using NanoString nCounter analysis for the PanCancer IO360 panel, and enrichment analysis were performed. Results: Eleven patients (36.7%) showed a durable clinical benefit (DCB), whereas 19 (63.3%) showed no durable benefit (NDB). TMB and enrichment scores (ES) showed significant differences between the DCB and NDB groups (p=0.044 and p=0.017, respectively); however, no significant correlations were observed among TMB, ES, and PD-L1. ES was the best single biomarker for predicting DCB (area under the curve [AUC], 0.794), followed by TMB (AUC, 0.679) and PD-L1 (AUC, 0.622). TMB and ES showed the highest AUC (0.837) among other combinations (AUC [TMB and PD-L1], 0.777; AUC [PD-L1 and ES], 0.763) and was similar to that of all biomarkers used together (0.832). Conclusion: The combination of TMB and ES may be an effective predictive tool to identify patients with NSCLC patients who would possibly benefit from ICI therapies.
참고문헌 (29)
- Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
- Rizvi NA, "Cancer immunology : mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
- Yarchoan M, "Tumor mutational burden and response rate to PD-1 inhibition", N Engl J Med, 377, pp.2500~2501 (2017)
- Hellmann MD, "Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer", Cancer Cell, 33, pp.853~861 (2018)
- Goodman AM, "Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers", Mol Cancer Ther, 16, pp.2598~2608 (2017)
- Hellmann MD, "Nivolumab plus ipilimumab in advanced non-small-cell lung cancer", N Engl J Med, 381, pp.2020~2031 (2019)
- Auslander N, "Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma", Nat Med, 24, pp.1545~1549 (2018)
- Jiang P, "Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response", Nat Med, 24, pp.1550~1558 (2018)
- Yu Y, "Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung xancer : a metaanalysis and individual patient-level analysis", JAMA Netw Open, 2, pp.e196879~ (2019)
- Lee JS, "Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1", JAMA Oncol, 5, pp.1614~1618 (2019)
- Lu S, "Comparison of biomarker modalities for predicting response to PD-1", PD-L1 checkpoint blockade : a systematic review and meta-analysis, 2019, pp.5, 1195~1204
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Hernandez-Prera JC, "Molecular determinants of thyroid nodules with indeterminate cytology and RAS mutations", Thyroid, 31, pp.36~49 (2021)
- Reich M, "GenePattern 2.0", Nat Genet, 38, pp.500~501 (2006)
- Kim H, "Increased CD3+ T cells with a low FOXP3+", CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients, 2019, pp.32, 367~375
- Ott PA, "T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers : KEYNOTE-028", J Clin Oncol, 37, pp.318~327 (2019)
- Feng YY, "Clinical implications of neoepitope landscapes for adult and pediatric cancers", Genome Med, 9, pp.77~ (2017)
- Turajlic S, "Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype : a pan-cancer analysis", Lancet Oncol, 18, pp.1009~1021 (2017)
- McGrail DJ, "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types", Ann Oncol, 32, pp.661~672 (2021)
- Dees S, "Regulatory T cell targeting in cancer : emerging strategies in immunotherapy", Eur J Immunol, 51, pp.280~291 (2021)
- Paluskievicz CM, "T regulatory cells and priming the suppressive tumor microenvironment", Front Immunol, 10, pp.2453~ (2019)
- Yarchoan M, "PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers", JCI Insight, 4, pp.e126908~ (2019)
- Gainor JF, "EGFR mutations and ALK rearrangements are associated with low response rtes to PD-1 pathway blockade in non-small cell lung cancer : a retrospective analysis", Clin Cancer Res, 22, pp.4585~4593 (2016)
- Dong ZY, "Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma", Clin Cancer Res, 23, pp.3012~3024 (2017)
- Skoulidis F, "STK11", LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma, 2018, pp.8, 822~835
- Papillon-Cavanagh S, "STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort", ESMO Open, 5, pp.e000706~ (2020)